Streetbeat News

Products Services

CARM

MRNA

Carisma Therapeutics Inc. (NASDAQ:CARM) and Moderna, Inc. (NASDAQ:MRNA) have announced the nomination of their first in vivo CAR-M development candidate targeting Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma. This nomination triggers a $2 million milestone payment to Carisma.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:32 pm

ASNS

Actelis Networks shares are trading higher following the announcement of a $300,000 order from a new channel partner in Italy for a national transportation infrastructure project.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:28 pm

ASNS

Actelis Networks has received an order exceeding $300K from a new Italian partner for a national transportation infrastructure project. The company continues its success with deployments for national highways in the UK, the Washington D.C. Department of Transportation, and recent orders from military bases and airports globally.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:26 pm

IBIT

Cryptocurrency markets are rallying ahead of the Trump-Biden U.S. Presidential election debate, with a Solana spot ETF application by VanEck as a key catalyst. Bitcoin, Ethereum, and Dogecoin are among the gainers. Notable developments include BlackRock's purchase of Bitcoin for its Global Allocation Fund and Coinbase suing the SEC and FDIC. Analysts caution about potential liquidations if Bitcoin drops to $60,700.

Portfolio Pulse from Khyathi Dalal

June 27, 2024 | 8:21 pm

DVAX

Dynavax has initiated a Phase 1/2 study for its novel shingles vaccine, Z-1018, to evaluate its safety, tolerability, and immunogenicity.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:10 pm

ACST

Acasti Pharma has reached 50% enrollment in its pivotal Phase 3 STRIVE-ON safety trial. This milestone is significant for the company's development of its lead drug candidate, GTX-104, aimed at treating subarachnoid hemorrhage. The trial's progress is a positive indicator for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:06 pm

FLR

Fluor has secured an EPCM services contract for Phase One of Northvolt's lithium-ion battery factory in Heide, Germany. Fluor will recognize its portion of the $4.8 billion project in Q2 2024, with completion scheduled for 2027.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:05 pm

ELTX

Elicio Therapeutics shares are trading lower following the announcement of preliminary disease-free survival analysis from the Phase 1a study of ELI-002 7P. The study showed that patients receiving ELI-002 7P at a dose of 4.9mg AMP-peptide had not yet reached the median DFS endpoint as of the May 24 cutoff date.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:03 pm

ELTX

Elicio Therapeutics announced preliminary disease-free survival (DFS) analysis from its Phase 1a study of ELI-002 7P. Patients receiving a 4.9mg dose of AMP-Peptide have not yet reached the median DFS endpoint as of the May 24 cutoff date.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:02 pm

LWAY

Pure Culture Organics (PCO) announced a victory as Lifeway Foods (LWAY) dismissed its lawsuit. PCO will now focus on new product developments, including kids kefir and collagen-enhanced pouches, and will launch new kefir flavors.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:01 pm